Drug delivery systems for the posterior segment of the eye: Fundamental basis and applications;Sistemas de transporte de drogas para o segmento posterior do olho: Bases fundamentais e aplicações

Arquivos Brasileiros de Oftalmologia

Volumn 70, Issue 1, 2007, Pages 173-179

  Fialho, Sílvia Ligório ^a   Cunha Jr , Armando da Silva ^a,b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Drug delivery systems; Eye diseases drug therapy; Iontophoresis; Liposomes

Indexed keywords

EID: 34147100224     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/s0004-27492007000100034     Document Type: Article

References (61)

1. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52(1):37-48.
2. Ogura Y. Drug delivery to the posterior segments of the eye. Adv Drug Deliv Rev. 2001;52(1):1-3.
3. Urtti A. Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 1993;37(6):435-56.
4. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol. 2000;27(7):558-62.
5. Ding S. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today. 1998:1(8):328-35.
6. Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev. 1995;16(1):3-19.
7. Foster CS, Maza MS. The sclera. New York: Springer-Verlag; c1994.
8. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36(9):1893-903.
9. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125(2):237-41.
10. Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ. et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41(5):1181-5.
11. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101(2):190-5.
12. Smith JR, George RK. Rosenbaum JT. Lower eyelid herniation of orbital fat may complicate periocular corticosteroid injection. Am J Ophthalmol. 2002; 133(6):845-7.
13. Gupta OP, Boynton JR, Sabini P, Markowitch W Jr, Quatela VC. Proptosis after retrobulbar corticosteroid injections. Ophthalmology. 2003;110(2):443-7.
14. Foulds WS. Moseley H, Eadie A, McNaught E. Vitreal, retinal, and pigment epithelial contribution to the posterior blood-ocular barrier. Trans Ophthalmol Soc U K. 1980:100(3):341-2.
15. Cunha-Vaz JG. The blood-ocular barriers: past, present, and future. Doc Ophthalmol. 1997-93(1-2):149-57.
16. Cunha-Vaz JG. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res. 2004;78(3):715-21.
17. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev. 1995;16(1):107-23.
18. Velez G. Whitcup SM. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol. 1999;83(11):1225-9.
19. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 2004;23(3):253-81.
20. Behar-Cohen F. Systèmes de délivrance des médicaments pour le segment antérieur: bases fondamentales et applications cliniques. J Fr Ophtalmol. 2002;25(5):537-44.
21. Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods. 1998;40(1):1-12.
22. Kimura H. Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica. 2001;215(3):143-55.
23. Merkli A, Tabatabay C, Gurny R, Heller J. Biodegradable polymers for the controlled release of ocular drugs. Prog Polym Sci. 1998;23(3):563-80.
24. Jain R, Shah NH, Malick AW. Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm. 1998;24(8):703-27.
25. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev. 1995;16:95-106.
26. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/ polyglycolic acid copolymers. Biomaterials. 1996,17(2):93-102.
27. Fialho SL, Rego MGB, Cardillo JA, Siqueira RC, Jorge R, Cunha Júnior AS. Implantes biodegradáveis destinados à administração intra-ocular. Arq Bras Oftalmol. 2003; 66(6):891-6.
28. Sanborn GE, Anand R, Torti RE, Nightingale SD, Cal SX, Yates B. et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol. 1992;110(2):188-95
29. Hashizoe M, Ogura Y, Kimura H, Moritera T, Honda Y, Kyo M. et al. Scleral plug of biodegradable polymers for controlled drug release in the vitreous Arch Ophthalmol. 1994;112(10):1380-4.
30. Rubsamen PE, Davis PA, Hernandez E, O'Grady GE, Cousins SW. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol. 1994;112(3): 407-13.
31. Cheng CK, Berger AS, Pearson PA, Ashton P, Jaffe GJ. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995;36(2):442-53.
32. Kunou N, Ogura Y, Hashizoe M, Honda Y, Hyon SH, Ikada Y. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J Control Release. 1995;37(1-2):143-50.
33. Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jaffe GJ. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998;116(1):69-77.
34. Zhou T, Lewis H, Foster RE, Schwendeman SP. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J Control Release. 1998;55(2-3):281-95.
35. Velez G, Whitcup SM. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol. 1999;83(11):1225-9.
36. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000: 107(11):2024-33.
37. Tan DT, Chee SP. Lim L, Theng J, Van Ede M. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology. 200;108 (12):2172-81.
38. Food and Drug Administration. FDA news. Product approvals. [cited 2005 Ago 8]. Available from: .
39. Kimura H, Ogura Y, Hashizoe M, Nishiwaki H, Honda Y, Ikada Y. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci. 1994;35(6):2815-9.
40. Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci. 2003;44(11):4845-52.
41. Tan DT, Chee SP, Lim L, Lim AS. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology. 1999;106(2):223-31.
42. The Wall Street Transcript. Dain rauscher wessels healthcare & life sciences special. CEO/COMPANY Interview. In: Donald J. Eaton. Oculex Pharmaceuticals, Inc: December 2000. [cited 2005 Aug 8]. Available from: http://www.twst.com/pdf/oculex.pdf#search='surodex%20approval'
43. Allergan Completes Acquisition of Oculex Pharmaceuticals, Inc. [text on the Internet]. USA: Allergan Inc; c2006. [cited 2006 Feb 1]. Available from: http://www.allergan.com/site/investors/ pr_details.asp?id=123213.
44. Fialho SL, da Silva Cunha A. Manufacturing techniques of biodegradable implants intended for intraocular application. Drug Deliv. 2005;12(2):109-16.
45. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev. 2001;52(1):5-16.
46. Refojo MF, Herrero-Vanrell R. Sustained delivery of ganciclovir from biodegradable poly (DL-lactide-co-glycolide) (PLGA) microspheres [abstract]. Invest Ophthalmol Vis Sci. 1996:37:18S.
47. Herrero-Vanrell R, Barcia E, Negro S, Refojo MF. Development of ganciclovir microspheres from poly(DL-lactide-co-glycolide) acid for the treatment of AIDS-related cytomegalovirus retinitis. STP Pharma Sciences. 1998;8237-40S.
48. Giordano GG, Refojo MF, Arroyo MH. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest Ophthalmol Vis Sci. 1993;34(9):2743-51.
49. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci. 1991;32(6):1785-90.
50. Khoobehi B, Stradtmann MO, Peyman GA, Aly OM. Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic Surg. 1991;22(3):175-80.
51. Colthurst MJ, Williams RL, Hiscott PS, Grierson I. Biomaterials used in the posterior segment of the eye. Biomaterials. 2000;21(7):649-65.
52. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154:123-40.
53. Full prescribing Information for Visudyne [text on the Internet]. St. Louis, MO NOVARTIS Pharmaceuticals Corporation; c2006. [cited 2005 Jul 4]. Available from: http//www.pharma.us.novartis.com/product/pi/pdf/ visudyne.pdf.
54. Ichikawa K, Takeuchi Y, Yonezawa S, Hikita T, Kurohane K, Namba Y, Oku N. Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. Cancer Lett. 2004;205(1):39-48.
55. Fialho SL, Cunha Júnior AS. Iontoforese no transporte ocular de drogas. Arq Bras Oftalmol. 2004;67(5):839-45.
56. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004;56(5):619-58. Review.
57. Lai PM, Roberts MS. Iontophoresis. In: Roberts MS. Dermal absorption and toxicity assessment New York: Marcel Dekker: 1998. p.371-414. [Drugs and the pharmaceutical sciences: a series of textbooks and monographs].
58. Sarraf D, Lee DA. The role of iontophoresis in ocular drug delivery. J Ocul Pharmacol. 1994;10(1):69-81.
59. Behar-Cohen F, El Aouni A, Le Rouic JF, Parel JM, Renard G, Chauvaud D. [Iontophoresis: past and future]. J Fr Ophtalmol. 2001;24(3):319-27. French.
60. Technology: Eyegate [text on the Internet]. Paris: EyeGate Pharma; c2005. [cited 2006 Feb 10]. Available form: http://www.eyegatepharma.com/ webpages/eyegate.htm
61. Fischer GA, Parkinson TM, Szlek MA. OcuPhor™ - The future of ocular drug delivery [text on the Internet]. [cited 2006 Feb 10]. Available from: http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=62. Drug delivery technology. Looking into iontophoresis [text on the Internet]. [cited 2006 Feb 10]. Available from: http://www.aciont.com/ DrugDelivery Technology042004.pdf.